TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse modelsarticle Published on 2024-08-072024-09-05 Journal: Emerging Microbes & Infections [Category] update2024, [키워드] bispecific antibody HBsAg suppression Hepatitis B virus TCR-like antibody Therapeutic antibody [DOI] 10.1080/22221751.2024.2387448 PMC 바로가기 [Article Type] article
A glycoengineered therapeutic anti-HBV antibody that allows increased HBsAg immunoclearance improves HBV suppression in vivoPharmacology Original Research Published on 2023-12-272024-09-05 Journal: Frontiers in Pharmacology [Category] update2024, [키워드] Chronic hepatitis B infection defucosylation HBsAg neutralization phagocytosis Therapeutic antibody [DOI] 10.3389/fphar.2023.1213726 PMC 바로가기 [Article Type] Pharmacology Original Research
Evaluation of a panel of therapeutic antibody clinical candidates for efficacy against SARS-CoV-2 in Syrian hamstersArticle Published on 2023-03-302024-09-05 Journal: Antiviral research [Category] update2024, [키워드] animal model antibody cocktail COVID-19 monoclonal antibody SARS-CoV-2 Therapeutic antibody [DOI] 10.1016/j.antiviral.2023.105589 PMC 바로가기 [Article Type] Article
Therapeutic antibodies – natural and pathological barriers and strategies to overcome them치료 항체 - 자연 및 병리학적 장벽 및 이를 극복하기 위한 전략Review Published on 2022-05-012022-09-12 Journal: Pharmacology & therapeutics [Category] COVID19(2023년), SARS, 진단, [키워드] administration antibodies antibody Antigen approved Biological Biological barriers cellular Efficacy expected Extracellular IMPROVE intravenously less overcome pandemic pathological Pathological barriers Patient SARS-CoV2 systemic side effect therapeutic Therapeutic antibody Therapeutic strategies therapy Treatment [DOI] 10.1016/j.pharmthera.2021.108022 PMC 바로가기 [Article Type] Review
ACE2-Fc fusion protein overcomes viral escape by potently neutralizing SARS-CoV-2 variants of concernACE2-Fc 융합 단백질은 우려되는 SARS-CoV-2 변이체를 강력하게 중화하여 바이러스 탈출을 극복합니다Article Published on 2022-03-012022-09-11 Journal: Antiviral Research [Category] COVID19(2023년), SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2-Fc Analysis antibodies Antibody drugs approved binding Biotechnology breakthrough infections caused Clinical data Comprehensive COVID-19 dominant variant drug drug design drug resistance Efficiency EMA experiment FDA fusion protein Glycoproteins increasingly Infectious disease Interaction mechanism monoclonal antibodies monoclonal antibody Mutation neutralization neutralize Neutralizing not compromised omicron overcome Protein binding Proteins public health remained SARS-CoV-2 variant SARS-CoV-2 virus spike variants tested the SARS-CoV-2 virus therapeutic therapeutic agent therapeutic antibodies Therapeutic antibody treat Treatment vaccinated individual vaccinated individuals Vaccine variant variants Viral viral escape viral infection [DOI] 10.1016/j.antiviral.2022.105271 PMC 바로가기 [Article Type] Article
The COVID-19/Tuberculosis Syndemic and Potential Antibody Therapy for TB Based on the Lessons Learnt From the Pandemic팬데믹에서 배운 교훈을 기반으로 한 COVID-19/결핵 증후군 및 결핵에 대한 잠재적 항체 치료Review Published on 2022-02-152022-09-12 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition affected antibody COVID-19 COVID-19 pandemic COVID-19/TB syndemic decrease Diagnosis diagnostics disease ENhance Escalation growth Health Immunotherapy impacted implication knowledge lesson Mental normality pandemic Pathogenesis physical Potential severity Symptoms syndemic T cell receptor (TCR)-like antibody Therapeutic antibody therapy Treatment Tuberculosis [DOI] 10.3389/fimmu.2022.833715 PMC 바로가기 [Article Type] Review
Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detectionCOVID-19 치료 및 SARS-CoV-2 검출을 위한 단일클론항체Review Published on 2022-01-042022-09-10 Journal: Journal of Biomedical Science [Category] SARS, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Angiotensin converting enzyme II (ACE2) antibody Antigen can be used coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus disease 2019 (COVID-19) COVID-19 COVID-19 pandemic COVID-19 therapeutic agents cytokine Cytokine storm Cytokine storms detect develop Diseases domain drug drugs effective exceptional expected Health crisis high mutation rate highlight immune response Immunoglobulin mAbs monoclonal antibodies monoclonal antibody mutation rate Neutralizing overactive pandemic powerful tool Prevent Prophylactic Protein public health crisis RBD Receptor binding motif (RBM) Receptor-binding domain Receptor-binding domain (RBD) reliability researcher respiratory resulting RNA virus SARS-CoV-2 SARS-CoV-2 detection SARS-COV-2 infection SARS-CoV-2 spike protein selective severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) severe disease progression specificity spike Spike protein spread of COVID-19 stimulate Surveillance the SARS-CoV-2 therapeutic therapeutic agents Therapeutic antibody therapy treat Treatment treatments for COVID-19 Vaccine Viral Viral detection viral infection [DOI] 10.1186/s12929-021-00784-w PMC 바로가기 [Article Type] Review
Comprehensive engineering of a therapeutic neutralizing antibody targeting SARS-CoV-2 spike protein to neutralize escape variants탈출 변이체를 중화하기 위해 SARS-CoV-2 스파이크 단백질을 표적으로 하는 치료 중화 항체의 포괄적 엔지니어링Article Published on 2022-01-012022-09-11 Journal: mAbs [Category] SARS, 변종, 진단, [키워드] addition antibodies antibody antibody engineering Bioavailability Comprehensive Concentration constant region Engineering escape variants. escaped highlight monoclonal antibody Mutation neutralization neutralize Neutralizing neutralizing antibody plasma half-life SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2 variant SARS-CoV-2 variants Spike protein subcutaneous injection the spike protein therapeutic therapeutic antibodies Therapeutic antibody These data variable region variant variants variants of SARS-CoV-2 [DOI] 10.1080/19420862.2022.2040350 PMC 바로가기 [Article Type] Article
Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding DomainSARS-CoV-2 스파이크 단백질 수용체 결합 도메인에 특이적인 인간 중화 항체의 구조적 기초Research Article Published on 2021-10-132022-09-10 Journal: Microbiology Spectrum [Category] MERS, SARS, 변종, 유전자 메커니즘, 진단, [키워드] ACE2 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 acute respiratory syndrome coronavirus-2 angiotensin Angiotensin-converting enzyme angiotensin-converting enzyme 2 antibodies antibody Antigen assist B cell B.1.1.7 back Basis bind binding caused complex conformation convalescent coronavirus coronavirus disease Coronavirus disease 2019 Coronavirus-2 COVID-19 COVID-19 pandemic crystal structure domain dominant drug drug candidate drug candidates drugs Economy effective Epitopes global health Health Human human Angiotensin-converting enzyme in vivo Intervention Lineage Lineage B.1.1.7 mAbs mechanism monoclonal antibodies monoclonal antibody Mutagenesis mutant NAbs native human monoclonal antibody Neutralizing activity neutralizing antibody neutralizing effect neutralizing epitope neutralizing monoclonal antibodies neutralizing monoclonal antibody New coronavirus not affect Prophylactic prophylactic and therapeutic efficacies RBD RBS-C receptor Receptor-binding domain Research residue respiratory Respiratory disease responsible reveal ridge S-RBD Safe SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike protein Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus Specific spike Spike protein the SARS-CoV-2 the spike protein Therapeutic antibody therapeutic efficacy Transgenic mouse understanding Vaccine Vaccine development variety [DOI] 10.1128/Spectrum.01352-21 PMC 바로가기 [Article Type] Research Article
Therapeutic effect of CT-P59 against SARS-CoV-2 South African variantSARS-CoV-2 남아프리카 변종에 대한 CT-P59의 치료 효과Article Published on 2021-08-202022-09-11 Journal: Biochemical and Biophysical Research Communication [Category] MERS, SARS, 변종, 진단, [키워드] 501Y.V2 African antibody Antiviral effect B.1.1.7 B.1.1.7 variant B.1.351 binding binding affinity circulation comparable COVID-19 patient COVID-19 patients CT-P59 decrease demonstrated dosage effective Efficacy immune evasion in vitro in vivo K417N less Live virus monoclonal antibody mutant Mutation N501Y neutralization assays neutralized Neutralizing activity Pseudovirus neutralization assay public health RBD Receptor binding domain reduced regdanvimab respiratory respiratory tracts SARS-CoV-2 SARS-CoV-2 virus shown South therapeutic therapeutic antibodies Therapeutic antibody therapeutic potential Transmissibility upper and lower respiratory tracts Vaccine variant variants variants of SARS-CoV-2 Viral Viral load virus wild type [DOI] 10.1016/j.bbrc.2021.06.016 PMC 바로가기 [Article Type] Article